Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 129.51% from the stock’s previous close.

Separately, EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Down 1.0 %

Shares of ANIX stock opened at $3.05 on Tuesday. Anixa Biosciences has a 12 month low of $2.14 and a 12 month high of $5.13. The firm has a market cap of $98.15 million, a PE ratio of -7.82 and a beta of 0.84. The stock has a 50 day moving average of $3.26 and a 200-day moving average of $2.99.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. As a group, equities analysts predict that Anixa Biosciences will post -0.42 EPS for the current fiscal year.

Institutional Trading of Anixa Biosciences

Large investors have recently bought and sold shares of the stock. Nations Financial Group Inc. IA ADV grew its position in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after acquiring an additional 7,500 shares during the period. Virtu Financial LLC grew its position in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the period. International Assets Investment Management LLC grew its position in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Concorde Asset Management LLC bought a new stake in Anixa Biosciences in the second quarter valued at $31,000. Finally, Tyler Stone Wealth Management grew its position in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.